Human Monoclonal Folate Receptor Beta Antibody

Back to all technologies

Bookmark/Download	Download as PDF
Track Code	65627
Categories	Biotechnology Medical/Health
Keywords	Anti-Inflammatory Antibodies Autoimmune Disease Biotechnology Drug Development Imaging Medical/Health Pharmaceuticals
Public Abstract	Folic acid is a vitamin required for the synthesis of DNA nucleotide bases and is essential for proliferation of all cells. To take in folic acid, some cells express a folate receptor that binds folic acid very tightly and carries it into the cell via endocytosis. There are four types of folate receptors: alpha; beta; gamma; delta, and these receptors are preferentially overexpressed on cancer cells. Purdue University researchers have developed a method for using a human monoclonal antibody against beta folate receptors. By targeting cancer cells and binding antibodies to the beta folate receptors on those cells, researchers can block some of the beta folate receptors on the cells. This lowers the amount of folic acid the cancer cell is receiving and prevents its rapid proliferation. By attaching chemical groups to the antibody, e.g. therapeutics or imaging agents, this approach can be used to potentially treat or identify cancers. It is particularly useful for targeting of chronic and acute leukemia, and has potential to treat these disorders, along with immunological conditions such as rheumatoid arthritis. Advantages: -Lowers the amount of folic acid cancer cells take in -Potential cancer treatment -Also treats inflammatory disorders
People	Low, Philip Stewart (Project leader) Dimitrov, Dimiter S Feng, Yang
Intellectual Property	Application Date Mar 14, 2018 Type DIV-Patent Country of Filing European Patent Patent Number 3401333 Issue Date May 19, 2021 Application Date Mar 14, 2018 Type EP-Patent Country of Filing Germany Patent Number 3401333 Issue Date May 19, 2021 Application Date Mar 14, 2018 Type EP-Patent Country of Filing Switzerland Patent Number 3401333 Issue Date May 19, 2021 Application Date Mar 14, 2018 Type EP-Patent Country of Filing United Kingdom Patent Number 3401333 Issue Date May 19, 2021 Application Date Apr 8, 2016 Type DIV-Patent Country of Filing United States Patent Number 9,963,505 Issue Date May 8, 2018 Application Date Oct 27, 2014 Type CON-Patent Country of Filing United States Patent Number 9,914,773 Issue Date Mar 13, 2018 Application Date Mar 8, 2013 Type CIP-Patent Country of Filing United States Patent Number 8,871,206 Issue Date Oct 28, 2014 Application Date May 3, 2018 Type CON-Patent Country of Filing United States Patent Number (None) Issue Date (None) Application Date Sep 9, 2011 Type PCT-Patent Country of Filing WO Patent Number (None) Issue Date (None) Application Date Sep 9, 2011 Type NATL-Patent Country of Filing European Patent Patent Number (None) Issue Date (None) Application Date Sep 9, 2010 Type Provisional-Patent Country of Filing United States Patent Number (None) Issue Date (None) Application Date (None) Type NATL-Patent Country of Filing United States Patent Number (None) Issue Date (None)
Contact OTC	Purdue Office of Technology Commercialization The Convergence Center 101 Foundry Drive, Suite 2500 West Lafayette, IN 47906 Phone: (765) 588-3475 Fax: (765) 463-3486 Email: otcip@prf.org